Evidence map›Paper›PMID 31526614›Full record

ArticleTrends in genetics : TIG2019

Surviving Telomere Attrition with the MiDAS Touch.

Rachel L Flynn, Christopher M Heaphy

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in genetics : TIG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Rachel L FlynnDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA; Department of Medicine, Boston University School of Medicine, Boston, MA, USA; Cancer Center, Boston University School of Medicine, Boston, MA, USA.
Christopher M HeaphyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: cheaphy@jhmi.edu.
Boston University · USJohns Hopkins University · US

Funding

Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres PathwayR01CA201446 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FLYNN, RACHEL L. · 2016 to 2022
$1.9M
NCI NIH HHS R01 CA201446
6 · The paper itself

Abstract

Cancer cells maintain telomere lengths through telomerase activity or by alternative lengthening of telomeres (ALT). Using an engineered model system, a recent study by Min et al. reveals that the combination of BLM-mediated DNA resection and telomere clustering, a characteristic of ALT telomeres, catalyzes RAD52-dependent mitotic DNA synthesis (MiDAS) specifically at telomeres to drive ALT activity.

Indexed as

TelomereDNADNA ReplicationTelomeraseTelomere HomeostasisTouchDNATelomerasealternative lengthening of telomeresBLMmitotic DNA synthesisRAD52SUMO

Identifiers

PMID31526614
OpenAlexW2972851019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.